Laboratorios Farmaceuticos Rovi, S.A. (ROVI.MC)
EUR 49.04
(-0.93%)
EUR 49.04
(-0.93%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 40.1 Million EUR | 175.95% |
| 2022 | -52.8 Million EUR | -103.97% |
| 2021 | -25.89 Million EUR | -227.19% |
| 2020 | 20.35 Million EUR | 18.01% |
| 2019 | 17.25 Million EUR | 128.15% |
| 2018 | -61.28 Million EUR | -2515.73% |
| 2017 | 2.53 Million EUR | 133.45% |
| 2016 | -7.58 Million EUR | -156.07% |
| 2015 | 13.52 Million EUR | 40.39% |
| 2014 | 9.63 Million EUR | -16.77% |
| 2013 | 11.57 Million EUR | -46.91% |
| 2012 | 21.8 Million EUR | 364.46% |
| 2011 | -8.24 Million EUR | 46.96% |
| 2010 | -15.54 Million EUR | -1158.79% |
| 2009 | -1.23 Million EUR | 93.71% |
| 2008 | -19.64 Million EUR | -495.57% |
| 2007 | 4.96 Million EUR | 732.48% |
| 2006 | -785 Thousand EUR | 100.0% |
| 2005 | -278.39 Billion EUR | -77830.88% |
| 2004 | -357.23 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 68.68 Million EUR | 71.27% |
| 2024 Q2 | 76.58 Million EUR | -164.9% |
| 2023 Q1 | -72.15 Million EUR | -36.64% |
| 2023 Q4 | 40.1 Million EUR | 450.97% |
| 2023 Q3 | 7.27 Million EUR | 108.34% |
| 2023 Q2 | -87.31 Million EUR | -21.0% |
| 2023 FY | 40.1 Million EUR | 175.95% |
| 2022 FY | -52.8 Million EUR | -103.97% |
| 2022 Q2 | -84.49 Million EUR | -186.98% |
| 2022 Q4 | -52.8 Million EUR | -119.86% |
| 2022 Q1 | -29.44 Million EUR | -13.73% |
| 2022 Q3 | -24.01 Million EUR | 71.58% |
| 2021 Q3 | -72.06 Million EUR | -33.68% |
| 2021 FY | -25.89 Million EUR | -227.19% |
| 2021 Q4 | -25.89 Million EUR | 64.08% |
| 2021 Q2 | -53.91 Million EUR | -53479.21% |
| 2021 Q1 | 101 Thousand EUR | -99.5% |
| 2020 Q3 | 39.61 Million EUR | -0.78% |
| 2020 Q4 | 20.35 Million EUR | -48.62% |
| 2020 Q1 | 20.72 Million EUR | 20.12% |
| 2020 Q2 | 39.92 Million EUR | 92.69% |
| 2020 FY | 20.35 Million EUR | 18.01% |
| 2019 FY | 17.25 Million EUR | 128.15% |
| 2019 Q3 | 1.82 Million EUR | 110.34% |
| 2019 Q1 | -20.55 Million EUR | 66.46% |
| 2019 Q2 | -17.6 Million EUR | 14.34% |
| 2019 Q4 | 17.25 Million EUR | 847.28% |
| 2018 Q1 | 1.45 Million EUR | -42.65% |
| 2018 Q2 | -10.57 Million EUR | -826.94% |
| 2018 FY | -61.28 Million EUR | -2515.73% |
| 2018 Q4 | -61.28 Million EUR | -378.02% |
| 2018 Q3 | 22.04 Million EUR | 308.41% |
| 2017 FY | 2.53 Million EUR | 133.45% |
| 2017 Q4 | 2.53 Million EUR | -13.5% |
| 2017 Q3 | 2.93 Million EUR | 158.81% |
| 2017 Q2 | -4.98 Million EUR | -237.08% |
| 2017 Q1 | 3.63 Million EUR | 147.97% |
| 2016 Q3 | -3.09 Million EUR | 36.74% |
| 2016 Q2 | -4.89 Million EUR | -423.48% |
| 2016 Q4 | -7.58 Million EUR | -145.12% |
| 2016 Q1 | 1.51 Million EUR | -88.82% |
| 2016 FY | -7.58 Million EUR | -156.07% |
| 2015 Q1 | 8.08 Million EUR | -16.1% |
| 2015 FY | 13.52 Million EUR | 40.39% |
| 2015 Q4 | 13.52 Million EUR | -27.16% |
| 2015 Q3 | 18.57 Million EUR | 98.31% |
| 2015 Q2 | 9.36 Million EUR | 15.83% |
| 2014 Q1 | 17.36 Million EUR | 49.97% |
| 2014 Q4 | 9.63 Million EUR | 6.44% |
| 2014 Q2 | -5000.00 EUR | -100.03% |
| 2014 Q3 | 9.05 Million EUR | 181140.0% |
| 2014 FY | 9.63 Million EUR | -16.77% |
| 2013 Q4 | 11.57 Million EUR | -19.95% |
| 2013 Q3 | 14.46 Million EUR | 49.2% |
| 2013 FY | 11.57 Million EUR | -46.91% |
| 2013 Q2 | 9.69 Million EUR | -39.02% |
| 2013 Q1 | 15.89 Million EUR | -27.1% |
| 2012 Q1 | 6.41 Million EUR | 177.76% |
| 2012 Q2 | -32.72 Million EUR | -610.48% |
| 2012 Q3 | 16.89 Million EUR | 151.61% |
| 2012 FY | 21.8 Million EUR | 364.46% |
| 2012 Q4 | 21.8 Million EUR | 29.08% |
| 2011 FY | -8.24 Million EUR | 46.96% |
| 2011 Q1 | 6.75 Million EUR | 143.45% |
| 2011 Q2 | -8.87 Million EUR | -231.4% |
| 2011 Q3 | -7.08 Million EUR | 20.16% |
| 2011 Q4 | -8.24 Million EUR | -16.36% |
| 2010 Q4 | -15.54 Million EUR | 0.0% |
| 2010 FY | -15.54 Million EUR | -1158.79% |
| 2009 FY | -1.23 Million EUR | 93.71% |
| 2008 FY | -19.64 Million EUR | -495.57% |
| 2007 FY | 4.96 Million EUR | 732.48% |
| 2006 FY | -785 Thousand EUR | 100.0% |
| 2005 FY | -278.39 Billion EUR | -77830.88% |
| 2004 FY | -357.23 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Atrys Health, S.A. | 212.17 Million EUR | 81.098% |
| Biotechnologies Assets SA | 6.81 Million EUR | -488.51% |
| Oryzon Genomics S.A. | 1.43 Million EUR | -2703.891% |
| Pharma Mar, S.A. | -16.65 Million EUR | 340.784% |